Health Care • Biotechnology: Pharmaceutical Preparations
$3.41 ▲ +0.14
(+4.28%)
MKT CAP: $179.1M • VOL: 946.1K
52W L $3 52W H $34
UPB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.9M | $2.4M | $2.4M |
| YoY Revenue Growth % | +20.4% | -0.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$160.4M | -$77.8M | -$40.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$143.4M | -$62.8M | -$20.5M |
| EBITDA (Normalized) | -$160.2M | -$77.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$133.3M | -$59.2M | -$37.9M |
| Capital Expenditures (CapEx) | $165.0K | $511.0K | — |
| Free Cash Flow (FCF) | -$133.4M | -$59.7M | -$37.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -42.7% | — |
| Cash & Short-Term Equivalents | $101.6M | $325.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $339.8M | $469.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR UPB.